Experimental Drug Targets Cancer Defenses in Mesothelioma Treatment
Mesothelioma is a rare and aggressive cancer most commonly associated with asbestos exposure. When asbestos fibers are inhaled, they can become trapped in the lungs, leading to chronic inflammation that may result in cancer decades later. Approximately 30,000 individuals are diagnosed with mesothelioma each year globally, and treatment options remain limited. While immunotherapy and chemotherapy can assist some patients, controlling the disease is still a significant challenge. The median survival for affected individuals is about 12 months, with a five-year survival rate of roughly 10 percent. Brian Cunniff, a professor at the University of Vermont (UVM), emphasizes the critical need for effective treatments for this condition. Recent research published in Nature Communications by Cunniff, UVM research scientist Victoria Gibson, and an international team of collaborators introduces an innovative strategy that could pave the way for new mesothelioma therapies. In a phase one clinical trial sponsored by RS Oncology, LLC, patients with relapsed mesothelioma received an experimental drug that successfully controlled disease progression in 67% of participants, with some experiencing tumor shrinkage. The drug was generally well tolerated, and critically ill patients in the trial showed improved survival compared to those receiving standard treatments. The approach taken by the UVM researchers is unique; instead of increasing antioxidants to combat cancer, they explored the effects of depriving cancer cells of their antioxidant defenses. Mesothelioma cells, like many cancer cells, produce high levels of reactive oxygen species (ROS), which can damage cells. To survive, these cancer cells increase the production of antioxidant enzymes, including peroxiredoxin 3 (PRX3), which operates within mitochondria—the energy-producing structures of cells. The researchers hypothesized that blocking PRX3 could lead to an accumulation of oxidative stress in tumor cells, ultimately overwhelming their defenses and causing cell death. The experimental treatment utilizes thiostrepton, a naturally occurring antibiotic, to inhibit PRX3, leading to an increase in hydrogen peroxide within the mitochondria of tumor cells, which can trigger their death. This strategy may be particularly effective against cancer cells, which already produce more ROS than normal cells. Laboratory experiments have shown that deleting PRX3 from mesothelioma cell lines impairs mitochondrial function and halts tumor growth in animal models, indicating the enzyme's crucial role in cancer cell survival. Importantly, previous research has demonstrated that eliminating PRX3 in healthy mice does not result in adverse effects, suggesting a potential therapeutic window for targeting this enzyme in cancer treatment. The scientific foundation for this treatment began at UVM's Cancer Center around 2015. Following early promising results with thiostrepton, researchers established RS Oncology to advance their discoveries into clinical testing. The team developed a clinical formulation known as RSO-021, which was tested in a phase one clinical trial in the UK between 2022 and 2023, overseen by the MHRA, the UK equivalent of the FDA. The drug is administered directly into the chest through a catheter, a method commonly used for mesothelioma patients who experience pleural effusions—fluid buildup in the chest cavity. This localized delivery allows for higher concentrations of the drug near the tumor while minimizing systemic exposure. The trial met its safety and tolerability goals, with no patient deaths attributed to the drug. Evidence from patient tissue confirmed that RSO-021 effectively targeted its intended biological pathway, mirroring results observed in laboratory and animal studies. The average progression-free survival in the trial was 4.2 months, comparable to existing treatments, but overall survival rates were notably better than those typically seen with current therapies. Cunniff described these findings as potentially transformative. The drug appears to possess both cytotoxic properties, directly killing tumor cells, and immunomodulatory effects, enhancing the immune system's ability to combat cancer. Phase two of the clinical trial has been completed, with results expected to be presented at an upcoming global oncology meeting. The research team is also exploring second-generation PRX3 inhibitors with improved solubility, which could be administered orally, expanding the treatment's potential applications beyond mesothelioma. Gibson, now a postdoctoral researcher, is investigating thiostrepton's effects on peritoneal malignancies, including gastric and gastrointestinal cancers. Cunniff believes the underlying mechanism may be applicable to other types of cancer, highlighting the broader implications of their research. Gibson reflects on the personal impact of their work, noting the emotional connection when a family member sought to enroll in the clinical trial, underscoring the real-world significance of their scientific endeavors. Materials provided by University of Vermont. Note: Content may be edited for style and length.




